Kim Rouven Liedtke

Dr. Kim Rouven Liedtke

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EFEric Freund
Eric Freund
KLKim Rouven Liedtke
Kim Rouven Liedtke
JLJulia van der Linde
Julia van der Linde
HMHans-Robert Metelmann
Hans-Robert Metelmann
CHClaus-Dieter Heidecke
Claus-Dieter Heidecke
Sander BekeschusSander Bekeschus
Sander Bekeschus
Metastatic colorectal cancer is the fourth most common cause of cancer death. Current options in palliation such as hyperthermic intraperitoneal chemotherapy (HIPEC) present severe side effects. Recent research efforts suggested the therapeutic use of oxidant-enriched liquid using cold physical plasma. To investigate a clinically accepted treatment regimen, we assessed the antitumor capacity of plasma-treated saline solution. In response to such liquid, CT26 murine colon cancer cells were readily oxidized and showed cell growth with subsequent apoptosis, cell cycle arrest, and upregulation of immunogenic cell death (ICD) markersin vitro. This was accompanied by marked morphological changes with re-arrangement of actin fibers and reduced motility. Induction of an epithelial-to-mesenchymal transition phenotype was not observed. Key results were confirmed in MC38 colon and PDA6606 pancreatic cancer cells. Compared to plasma-treated saline, hydrogen peroxide was inferiorly toxic in 3D tumor spheroids but of similar efficacy in 2D models.In vivo, plasma-treated saline decreased tumor burden in Balb/C mice. This was concomitant with elevated numbers of intratumoral macrophages and increased T cell activation following incubation with CT26 cellsex vivo. Being a potential adjuvant for HIPEC therapy, our results suggest oxidizing saline solutions to inactivate colon cancer cells while potentially stimulating antitumor immune responses.

16 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KLKim Rouven Liedtke
Kim Rouven Liedtke
Sander BekeschusSander Bekeschus
Sander Bekeschus
AKAndré Kaeding
André Kaeding
CHChristine Hackbarth
Christine Hackbarth
JKJens-Peter Kuehn
Jens-Peter Kuehn
LPLars Ivo Partecke
Lars Ivo Partecke
Pancreatic cancer is associated with a high mortality rate. In advanced stage, patients often experience peritoneal carcinomatosis. Using a syngeneic murine pancreatic cancer cell tumor model, the effect of non-thermal plasma (NTP) on peritoneal metastatic lesions was studied. NTP generates reactive species of several kinds which have been proven to be of relevance in cancer. In vitro, exposure to both plasma and plasma-treated solution significantly decreased cell viability and proliferation of 6606PDA cancer cells, whereas mouse fibroblasts were less affected. Repeated intraperitoneal treatment of NTP-conditioned medium decreased tumor growth in vivo as determined by magnetic resonance imaging, leading to reduced tumor mass and improved median survival (61 vs 52 days; p < 0.024). Tumor nodes treated by NTP-conditioned medium demonstrated large areas of apoptosis with strongly inhibited cell proliferation. Contemporaneously, no systemic effects were found. Apoptosis was neither present in the liver nor in the gut. Also, the concentration of different cytokines in splenocytes or blood plasma as well as the distribution of various hematological parameters remained unchanged following treatment with NTP-conditioned medium. These results suggest an anticancer role of NTP-treated solutions with little to no systemic side effects being present, making NTP-treated solutions a potential complementary therapeutic option for advanced tumors.

1 September 2018 in Clinical Plasma Medicine
Verified
Journal Article
Closed access
KLKim Rouven Liedtke
Kim Rouven Liedtke
EFEric Freund
Eric Freund
CHChristine Hackbarth
Christine Hackbarth
CHClaus-Dieter Heidecke
Claus-Dieter Heidecke
LPLars-Ivo Partecke
Lars-Ivo Partecke
Sander BekeschusSander Bekeschus
Sander Bekeschus

1 October 2018 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
KLKim Rouven Liedtke
Kim Rouven Liedtke
SDStephan Diedrich
Stephan Diedrich
OPOnur Pati
Onur Pati
EFEric Freund
Eric Freund
RFRobert Flieger
Robert Flieger
Sander BekeschusSander Bekeschus
Sander Bekeschus
Background/Aim: Poor prognosis of pancreatic cancer has remained almost unchanged in recent years. Cold physical plasma was suggested as an innovative anticancer strategy, but its selective killing activity of malignant over non-malignant cells has only partially been explored. The present study aimed at exploring the effect of cold physical plasma on cellular viability. Materials and Methods: Induction of cell death and apoptosis by cold physical plasma was investigated in murine PDA6606 pancreatic cancer cells and primary murine fibroblasts in vitro (2D and 3D cultures) and in ovo. Results: Plasma increased apoptosis in PDA6606 to a significantly higher extent compared to fibroblasts. Antioxidants abrogated these effects, suggesting a prime role of reactive oxygen species in plasma-induced apoptosis. Plasma increased apoptosis of 3D PDA6606 multicellular spheres grown in vitro and in ovo, to significantly higher rates compared to that of fibroblasts, with minimum in ovo inflammation or necrosis observed by hematoxylin and eosin staining (H&E). Conclusion: These data support the future intra-operative application of cold physical plasma for the treatment of microscopic residual tumor tissue after surgical resection.

2 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
KLKim Rouven Liedtke
Kim Rouven Liedtke
EFEric Freund
Eric Freund
MHMaraike Hermes
Maraike Hermes
SOStefan Oswald
Stefan Oswald
CHClaus-Dieter Heidecke
Claus-Dieter Heidecke
Sander BekeschusSander Bekeschus
Sander Bekeschus
Pancreatic cancer is one of the most aggressive tumor entities. Diffuse metastatic infiltration of vessels and the peritoneum restricts curative surgery. Standard chemotherapy protocols include the cytostatic drug gemcitabine with limited efficacy at considerable toxicity. In search of a more effective and less toxic treatment modality, we tested in human pancreatic cancer cells (MiaPaca and PaTuS) a novel combination therapy consisting of cytostatic drugs (gemcitabine or cisplatin) and gas plasma-conditioned Ringer’s lactate that acts via reactive oxygen species. A decrease in metabolic activity and viability, change in morphology, and cell cycle arrest was observed in vitro. The combination treatment was found to be additively toxic. The findings were validated utilizing an in ovo tumor model of solid pancreatic tumors growing on the chorion-allantois membrane of fertilized chicken eggs (TUM-CAM). The combination of the drugs (especially cisplatin) with the plasma-conditioned liquid significantly enhanced the anti-cancer effects, resulting in the induction of cell death, cell cycle arrest, and inhibition of cell growth with both of the cell lines tested. In conclusion, our novel combination approach may be a promising new avenue to increase the tolerability and efficacy of locally applied chemotherapeutic in diffuse metastatic peritoneal carcinomatosis of the pancreas.

24 May 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
MKMarie-Luise Kromrey
Marie-Luise Kromrey
KLKim Rouven Liedtke
Kim Rouven Liedtke
TITill Ittermann
Till Ittermann
SLSönke Langner
Sönke Langner
MKMichael Kirsch
Michael Kirsch
JKJens-Peter Kühn
Jens-Peter Kühn